MiNK Therapeutics receives Nasdaq MVLS deficiency notice; has until March 12, 2025 to comply

MiNK Therapeutics, Inc.

Received Nasdaq letter on September 13, 2024 for failing MVLS (minimum value of listed securities) requirement.
MVLS was below $35 million for 30 consecutive trading days, violating Nasdaq Listing Rule 5550(b)(2).
Company has 180 calendar days, until March 12, 2025, to regain compliance.
To comply, MVLS must be $35M or more for at least 10 consecutive trading days.
Failure to cure may lead to delisting; company may then appeal to a Hearings Panel.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.